Ascletis Pharma Inc (1672)

Hong Kong
Currency in HKD
4.54
+0.26(+6.07%)
Closed
1672 Scorecard
Full Analysis
Management has been aggressively buying back shares
Unusual trading volume
Fair Value
Day's Range
4.254.60
52 wk Range
0.764.60
Key Statistics
Edit
Bid/Ask
4.54 / 4.59
Prev. Close
4.54
Open
4.28
Day's Range
4.25-4.6
52 wk Range
0.76-4.6
Volume
6.39M
Average Volume (3m)
3.03M
1-Year Change
132.61%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1672 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
3.95
Downside
-13.07%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet
Show more

Ascletis Pharma Company Profile

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People’s Republic of China.

Employees
219
Market
Hong Kong

Compare 1672 to Peers and Sector

Metrics to compare
1672
Peers
Sector
Relationship
P/E Ratio
−14.9x−16.4x−0.7x
PEG Ratio
1.42−0.030.00
Price/Book
1.8x2.2x2.6x
Price / LTM Sales
381.4x8.2x3.1x
Upside (Analyst Target)
−13.4%57.5%47.6%
Fair Value Upside
Unlock11.0%7.7%Unlock

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 3.95
(-13.07% Downside)

Earnings

Latest Release
Nov 27, 2024
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Ascletis Pharma (1672) Stock Price Today?

The Ascletis Pharma stock price today is 4.54.

What Stock Exchange Does Ascletis Pharma Trade On?

Ascletis Pharma is listed and trades on the Hong Kong stock exchange.

What Is the Stock Symbol for Ascletis Pharma?

The stock symbol for Ascletis Pharma is "1672."

What Is the Ascletis Pharma Market Cap?

As of today, Ascletis Pharma market cap is 4.37B.

What is Ascletis Pharma Earnings Per Share?

The Ascletis Pharma EPS is -0.249.

What Is the Next Ascletis Pharma Earnings Date?

Ascletis Pharma will release its next earnings report on 23 Mar 2025.

From a Technical Analysis Perspective, Is 1672 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.